Research programme: influenza vaccines - MedImmune/sanofi pasteur

Drug Profile

Research programme: influenza vaccines - MedImmune/sanofi pasteur

Latest Information Update: 18 Mar 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator sanofi pasteur
  • Developer MedImmune; sanofi pasteur
  • Class
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Influenza virus infections

Most Recent Events

  • 18 Mar 2009 No development reported - Preclinical for Influenza virus infections in USA (unspecified route)
  • 19 Jun 2007 MedImmune has been acquired by AstraZeneca
  • 02 Apr 2007 Preclinical trials in Influenza virus infections treatment in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top